Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition
Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...
Targeted Oncology57 分钟
Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL
SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.